<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150471</url>
  </required_header>
  <id_info>
    <org_study_id>DAS-CHANGE</org_study_id>
    <nct_id>NCT04150471</nct_id>
  </id_info>
  <brief_title>Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients</brief_title>
  <official_title>An Open Label, Observational Clinical Study to Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Have Any Grade of Adverse Events and Early Molecular Response Within 3 Months of Frontline Dasatinib Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in patients with newly diagnosed CP CML (Chronic Phase Chronic&#xD;
      Myeloid Leukemia) who have achieved EMR (&lt; 10% IS BCR-ABL) at 3 months after first line&#xD;
      treatment with dasatinib. Subjects will be allocated to 80mg QD based on EMR (Early Molecular&#xD;
      Response) achievement and early safety profile following a standard of care approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will sign the consent forms for screening prior to frontline dasatinib therapy (1st)&#xD;
      and the 3 month molecular test date (2nd). The molecular samples will be analyzed in the&#xD;
      central lab as part of the screening procedure.&#xD;
&#xD;
      Subjects will be treated for a maximum of 60 months after allocation of the last subject on&#xD;
      the assigned regimen (dasatinib 80mg QD), unless disease progression, treatment failure or&#xD;
      unacceptable toxicity occurs, the subject withdraws consent, or the study is discontinued by&#xD;
      the sponsor. Subjects who discontinue study therapy early due to disease progression or&#xD;
      intolerance to study medication will continue to be followed yearly for survival for up to 5&#xD;
      years after allocation of the last subject. All subjects will be followed yearly for&#xD;
      progression-free survival and overall survival.&#xD;
&#xD;
      For patients who continue their assigned treatment, safety assessments will be conducted&#xD;
      every 6 months and cytogenetic assessment as investigator assessment.&#xD;
&#xD;
      Follow up visits after the last dose of study drug will be required at least every 4 weeks&#xD;
      until all study related toxicities resolve to baseline (or CTC Grade ≤ 1), stabilize or are&#xD;
      deemed irreversible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of MMR</measure>
    <time_frame>12 month</time_frame>
    <description>Level of Bcr-Abl transcript (Conventional Q-RT-PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess: Number and percentage of participants with treatment-related adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>12 months</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMR and MR4.5 rates by 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>Level of Bcr-Abl transcript (Conventional Q-RT-PCR)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Chronic Myelocytic Leukemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis</intervention_name>
    <description>Conventional Q-RT-PCR every 3 months</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Rest of RNA samples after Q-RT-PCR (Quantitative Real-time Polymerase chain reaction)&#xD;
      analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult CML-CP Ph+ patients with BCR-ABL1 will start frontline dasatinib 100mg QD treatment.&#xD;
        Dasatinib monotherapy must have been started within 3 months of CP-CML diagnosis. Patients&#xD;
        having BCR-ABL1 transcript level &lt; 10% IS (International Standard) after 3 months of&#xD;
        treatment with frontline dasatinib will reduce dasatinib dose to 80mg QD and all of&#xD;
        patients must have any grade of adverse events at 3 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult CML-CP Ph+ (Philadelpia) patients with BCR-ABL1 patients diagnosed within 3&#xD;
             months&#xD;
&#xD;
          -  Adequate renal function defined as serum creatinine ≤ 3 times the institutional&#xD;
             ULN(Upper limit of normal)&#xD;
&#xD;
          -  Adequate hepatic function defined as: total bilirubin ≤ 2 times the institutional ULN;&#xD;
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the&#xD;
             institutional upper limit of normal (ULN).&#xD;
&#xD;
          -  Adequate cardiac function (see exclusion criteria)&#xD;
&#xD;
          -  Adequate pulmonary function (see exclusion criteria)&#xD;
&#xD;
          -  Serum Na, K, Mg, and total serum Ca or ionized Ca levels must be greater than or equal&#xD;
             to the institutional lower limit of normal. Subjects with low K, Mg levels, total&#xD;
             serum Ca and/or ionized Ca must be replete to allow for protocol entry: Rescreening is&#xD;
             permitted in the event of temporary biochemical abnormalities&#xD;
&#xD;
          -  CML-CP Ph+ patients with CHR but with BCR-ABL level &lt; 10% IS after 3 months of&#xD;
             frontline dasatinib 100 mg treatment. And currently persisting any grade adverse&#xD;
             events to dasatinib 100 mg QD&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group) performance status 0-2&#xD;
&#xD;
          -  Women must not be pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous diagnosis of accelerated phase or blast crisis&#xD;
&#xD;
          -  Documented any major ABL1 mutation&#xD;
&#xD;
          -  A serious uncontrolled medical disorder or active infection that would impair the&#xD;
             ability of the subject to receive dasatinib&#xD;
&#xD;
          -  Pulmonary arterial hypertension&#xD;
&#xD;
          -  Congenital bleeding disorders&#xD;
&#xD;
          -  Prior or concurrent malignancy, except for the following&#xD;
&#xD;
          -  Subject with any anti-CML other than dasatinib&#xD;
&#xD;
          -  Subjects with prior stem cell transplantation and/or high dose chemotherapy for CML&#xD;
&#xD;
          -  Subjects currently taking drugs that are generally accepted to have a risk of causing&#xD;
             Torsades de Pointes&#xD;
&#xD;
          -  Subjects who were previously treated with over 100mg at second phase screening&#xD;
&#xD;
          -  Subjects who are not tolerable to 80mg at second phase screening&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding or likely to become pregnant&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg, infectious disease) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sahee Park</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Research Institute, The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Wook Kim</last_name>
    <phone>+82-2-2258-7030</phone>
    <email>dwkim@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahee Park, MS</last_name>
      <phone>+82-2-2258-7622</phone>
      <email>saheepark@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong-Wook Kim, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23.</citation>
    <PMID>27217448</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Wook Kim</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

